Latest Conference Articles

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the overall survival results from the phase III TIVO-1 study that compared tivozanib to sorafenib in patients with renal cell carcinoma.

The addition of dasatinib to standard therapy with docetaxel failed to improve survival and most other clinical endpoints in men with metastatic castration-resistant prostate cancer in the phase III READY trial.

An updated interim analysis of the COU-AA-302 trial upholds the benefits of abiraterone acetate in mildly symptomatic or asymptomatic patients with progressive mCRPC untreated with prior chemotherapy.

Use of corticosteroids had a negative impact on outcomes with enzalutamide treatment as well as placebo treatment in men with metastatic castrate resistant prostate cancer.

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the third interim analysis of the COU-AA-302 trial that examined abiraterone acetate before chemotherapy in mCRPC.

Abdenour Nabid, MD, from the Centre Hospitalier de Universitaire de Sherbrooke in Sherbrooke, Canada, discusses results of a phase III randomized study that compared 18 months of ADT to 36 in men with high-risk, localized prostate cancer.

Small renal masses identified in elderly patients can be safely managed by surveillance and maintain the same mortality risk as those who undergo surgery, suggesting that surgery could be avoided altogether in many patients.

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, discusses the implications of a large study looking at the detection of prostate cancer using prostate biopsies.

Shortening the course of androgen blockade therapy from 36 months to 18 months when combined with radiation therapy does not appear to compromise outcomes in patients with high-risk prostate cancer

A large, retrospective study has found that high-risk prostate cancer that can only be detected through PSA testing is more likely to occur among men over the age of 75 and in African Americans.

Francesco Lo-Coco, MD, Hematology, University Tor Vergata, discusses a new emerging treatment, arsenic trioxide, in acute promyelocytic leukemia.

Ghassan K. Abou-Alfa, MD, from Memorial Sloan-Kettering Cancer Center, discusses a study that examined the utility of doxorubicin-eluting beads in hepatic arterial embolization as a treatment for hepatocellular carcinoma.

The 2013 Gastrointestinal Cancers Symposium was held at the Moscone West Building, San Francisco, CA, from January 24-26.

Adding nab-paclitaxel to gemcitabine improves survival compared with gemcitabine alone in patients with metastatic pancreatic cancer.

Ramucirumab significantly extended overall survival as a second-line agent in patients with metastatic gastric or gastroesophageal junction adenocarcinoma that progressed on first-line therapy.

Patients with metastatic colorectal cancer whose disease had progressed despite treatment with oxaliplatin experienced an improvement in survival by switching to a regimen of ziv-aflibercept plus FOLFIRI.

Axel Grothey, MD, from the Mayo Clinic, Rochester, Minnesota, discusses the time course of adverse events following treatment with regorafenib, as observed in the CORRECT study.

Adjuvant chemotherapy with the oral fluoropyrimidine S-1 improved survival versus standard postoperative gemcitabine in Asian patients with pancreatic cancer, according to an interim analysis from a phase III trial conducted in Japan.

Ramesh K. Ramanathan, MD, from the Virginia G. Piper Cancer Center, discusses the phase III MPACT study that examined gemcitabine plus nab-paclitaxel in patients with metastatic adenocarcinoma of the pancreas.

William M. Grady, MD, from the Fred Hutchinson Cancer Research Center, discusses results from a study that examined the association of intrinsic subtypes of colorectal cancer with prognosis, chemotherapy response, and other factors.

A simple blood draw could lead to life-prolonging adjustments in treatment for patients with pancreatic cancer, the authors of a study have found.

Using a new classification system that categorizes colorectal cancers by tumor gene expression patterns, researchers have determined that tumor prognosis and response to adjuvant chemotherapy in CRC vary according to molecular subtype.

Patients with advanced esophagogastric adenocarcinoma who received docetaxel as a second-line therapy experienced a longer period of overall survival as well as a better quality of life compared with patients who received active symptom control.

A retrospective analysis of the potential benefits of surgery following treatment with imatinib (Gleevec) suggests a clear benefit in both OS and PFS in patients with metastatic or recurrent GIST when compared with those who received imatinib therapy alone.

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, discusses the trials investigating ABT-199 and ibrutinib that were presented at the 2012 American Society of Hematology (ASH) Meeting.

Proposed federal budget cuts that could affect the National Institutes of Health, and thus hematology/oncology research, were highlighted as an area of concern during the 54th Annual Meeting of the American Society of Hematology in Atlanta, Georgia.

Photos from the 54th American Society of Hematology (ASH) Annual Meeting and Exposition, held at the Georgia World Congress Center, Atlanta, GA, from December 8-11, 2012.

Carlos L. Arteaga, MD, from Vanderbilt-Ingram Cancer Center, describes key takeaway points for practicing oncologists, clinical investigators, and scientists from the 2012 SABCS.

Photos from the 35th annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), held at the Henry B. Gonzalez Convention Center, San Antonio, TX, from December 4-8, 2012.

Researchers have demonstrated that ponatinib can overcome a wide range of mutations that cause treatment resistance-including the stubborn T315I mutation-in all stages of CML and Ph+ ALL.